Mr. Bill Dickie reports
ADVANCED PROTEOME THERAPEUTICS PROVIDES OVERVIEW OF CURRENT ACTIVITIES AND STRATEGIC OBJECTIVES
Advanced Proteome Therapeutics Corp. has provided an overview of current projects prior to more detailed news releases that will be disclosed shortly.
Advanced Proteome Therapeutics' site-selective technology is being employed in the emergent field of radioimmunoconjugates (radioactive substances that can carry radiation directly to cancer cells). These conjugates are made by attaching a radioactive entity to a monoclonal antibody. They may be used for imaging to help find cancer cells in the body and/or as therapies to destroy them. Advanced Proteome Therapeutics' programs offer a competitive advantage, as they are intended to create well-defined, chemically controlled constructs. Such radioimmunoconjugates are expected to display higher selectivity and efficiency than have previously been available in this field, pursuant to a multi-billion-dollar market.
Advanced Proteome Therapeutics' programs involving entities emitting alpha and beta particles are proceeding on two fronts. The recently announced collaboration with Noria Pharmaceuticals is focused on site-selectively targeting the alpha emitting isotope, Actinium-225, to cancer cells, an approach with several potential advantages over existing radiotherapies. The company is independently pursuing complementary beta particle therapy with Lutetium-177, a well-established targeted therapy, as well as other such radionuclides. News from Advanced Proteome Therapeutics on this front will be released imminently.
Collaboration with Heidelberg Pharma
Antibody-drug conjugates (ADCs) targeted for cancer indications have been actively pursued for two decades, but have suffered from stability problems and product heterogeneity. Nevertheless, even a highly heterogeneous first-generation ADC has had clinical and commercial impact with sales near $1-billion (U.S.) per year, highlighting the great opportunity for improved versions. The combination of Advanced Proteome Therapeutics' proprietary site-selective protein modification technology and Heidelberg Pharma's proprietary ATAC technology, featuring the mushroom toxin amanitin, has yielded novel antibody-amanitin conjugates of high purity and chemical stability. Controlled conjugation methods have led to conjugates that possess high target-specific cytotoxic potency against three cancer cell lines. An antibody-amanitin conjugate has been scaled up for testing in animal tumour models, which has proceeded beyond the fourth quarter (ended July 31). Initial results from these studies are still being tabulated, but are nearing completion, and will be reported on as soon as the analysis of data is completed within the next few weeks.
Advanced Proteome Therapeutics and ImmunoBiochem Corp. (IBC) have entered into a collaboration and option agreement to develop superior antibody-drug conjugates targeted for difficult-to-treat triple-negative breast cancer, which constitutes 10 per cent to 20 per cent of breast cancers. The collaboration is geared toward site-selectively modifying the composition of IBC's award-winning antibody technology. It is intended to obtain purer versions of ADCs, directed toward an unusual and highly novel extracellular target. Feasibility studies toward constructing site-selectively attached linker-toxin combinations to ImmunoBiochem's novel antibody are under way and sufficient clarity bearing on biological testing should emerge over the next several weeks.
About Advanced Proteome Therapeutics Corp.
Advanced Proteome is developing a proprietary technology to directly target cancerous tumours and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity and lower toxicity than other therapies that can also attack healthy cells. Advanced Proteome is working to streamline the process by which these agents are prepared, which to date has been extremely cumbersome, limiting their potential.
© 2021 Canjex Publishing Ltd. All rights reserved.